Albertine Donker

Rare Inherited Iron and Heme-related Anemias 125 3 anemia. Blood. 2014;123(3):326-333. 21. Heeney MM, Campagna DR, Westerman M, Fleming MD. The clinical and genetic spectrum of TMPRSS6 mutations leading to inappropriate hepcidin expression and iron refractory iron deficiency anemia (IRIDA). Paper presented at: Blood 2009. 22. Beutler E, Van Geet C, te Loo DM, et al. Polymorphisms and mutations of human TMPRSS6 in iron deficiency anemia. Blood cells, molecules & diseases. 2010;44(1):16-21. 23. Cau M, Galanello R, Giagu N, Melis MA. Responsiveness to oral iron and ascorbic acid in a patient with IRIDA. Blood cells, molecules & diseases. 2012;48(2):121-123. 24. Locatelli F, Barany P, Covic A, et al. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2013;28(6):1346-1359. 25. Lehmberg K, Grosse R, Muckenthaler MU, et al. Administration of recombinant erythropoietin alone does not improve the phenotype in iron refractory iron deficiency anemia patients. Annals of hematology. 2013;92(3):387-394. 26. Ramsay AJ, Quesada V, Sanchez M, et al. Matriptase-2 mutations in iron-refractory iron deficiency anemia patients provide new insights into protease activation mechanisms. Human molecular genetics. 2009;18(19):3673-3683. 27. Kroot JJ, Tjalsma H, Fleming RE, Swinkels DW. Hepcidin in human iron disorders: diagnostic implications. Clinical chemistry. 2011;57(12):1650-1669. 28. Wallace DF, Harris JM, Subramaniam VN. Functional analysis and theoretical modeling of ferroportin reveals clustering of mutations according to phenotype. American journal of physiology Cell physiology. 2010;298(1):C75- 84. 29. De Domenico I, Ward DM, Langelier C, et al. The molecular mechanism of hepcidin-mediated ferroportin down- regulation. Molecular biology of the cell. 2007;18(7):2569-2578. 30. Pietrangelo A. The ferroportin disease. Blood cells, molecules & diseases. 2004;32(1):131- 138. 31. Camaschella C, Poggiali E. Rare types of genetic hemochromatosis. Acta haematologica. 2009;122(2-3):140-145. 32. Mayr R, Janecke AR, Schranz M, et al. Ferroportin disease: a systematic meta- analysis of clinical and molecular findings. Journal of hepatology. 2010;53(5):941-949. 33. Nemeth E. Ferroportin mutations: a tale of two phenotypes. Blood. 2005;105(10):3763- 3764. 34. Rice AE, Mendez MJ, Hokanson CA, Rees DC, Bjorkman PJ. Investigation of the biophysical and cell biological properties of ferroportin, a multipass integral membrane protein iron exporter. Journal of molecular biology. 2009;386(3):717-732. 35. Blanc B, Finch CA, Hallberg L et al. Nutritional Anemias. Report of a WHO Scientific Group. WHO Technical Report Series. 1968;405:1-40. 36. Harris ZL, Durley AP, Man TK, Gitlin JD. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. Proceedings of the National Academy of Sciences of the United States of America. 1999;96(19):10812-10817. 37. De Domenico I, Ward DM, di Patti MC, et al. Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-ceruloplasmin. The EMBO journal. 2007;26(12):2823-2831. 38. Miyajima H, Kohno S, Takahashi Y, Yonekawa O, Kanno T. Estimation of the gene frequency of aceruloplasminemia in Japan. Neurology. 1999;53(3):617-619. 39. McNeill A, Pandolfo M, Kuhn J, Shang H, Miyajima H. The neurological presentation of ceruloplasmin gene mutations. European neurology. 2008;60(4):200-205.